The Effects of the Female Hormones on Cerebral Perfusion

NCT ID: NCT03299179

Last Updated: 2023-12-06

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Total Enrollment

62 participants

Study Classification

OBSERVATIONAL

Study Start Date

2016-10-03

Study Completion Date

2027-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Measuring brain perfusion is biased by a inter- and intrasubject variability, caused by physiological and lifestyle factors. In this study, the investigators want to investigate the variations in cerebral perfusion and other brain parameters (grey matter, resting-state brain activity, brain connectivity and white matter diffusion) caused by the female sex hormones and hormonal contraception.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Cerebral Perfusion Contraception Menstrual Cycle

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

CASE_CONTROL

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Natural cycle

15 female volunteers, not using hormonal contraception, will be scanned during 3 menstrual cycles. During each cycle, the volunteers will be scanned 3 times: during the follicular phase, during ovulation and during luteal phase.

MRI scan

Intervention Type DEVICE

Several MRI scan modalities: MPRAGE (structural scan), arterial spin labeling (cerebral perfusion), resting state functional-MRI (fMRI, cerebral activity) and diffusion MRI (white matter diffusion and white matter tracts).

Physiological monitoring

Intervention Type DEVICE

During MRI: heart rate, end-tidal carbon dioxide (CO2), respiratory rate and skin conductance

Blood sample

Intervention Type BIOLOGICAL

Blood sample after MRI-session: measurement of hematocrit, hemoglobin, estradiol, progesterone, follicle stimulation hormone and luteinizing hormone.

Blood pressure measurement

Intervention Type DEVICE

Measuring blood pressure before and after MRI-scan

Body temperature

Intervention Type DEVICE

Measuring body temperature before and after MRI-scan

Questionnaires

Intervention Type OTHER

Questionnaires at the start of the study on lifestyle. Additionally, a questionnaire before each scan session on the actual state of the volunteer (e.g. mood, caffeine consumption, alcohol, medication, etc.)

Pregnancy test

Intervention Type DIAGNOSTIC_TEST

Test for pregnancy using a pregnancy dipstick test

Anti-conception

15 female volunteers, using hormonal contraception pill Deso 20, will be scanned during 3 menstrual cycles. During each cycle, the volunteers will be scanned 2 times: during the pill-week and during the pill-free week.

MRI scan

Intervention Type DEVICE

Several MRI scan modalities: MPRAGE (structural scan), arterial spin labeling (cerebral perfusion), resting state functional-MRI (fMRI, cerebral activity) and diffusion MRI (white matter diffusion and white matter tracts).

Physiological monitoring

Intervention Type DEVICE

During MRI: heart rate, end-tidal carbon dioxide (CO2), respiratory rate and skin conductance

Blood sample

Intervention Type BIOLOGICAL

Blood sample after MRI-session: measurement of hematocrit, hemoglobin, estradiol, progesterone, follicle stimulation hormone and luteinizing hormone.

Blood pressure measurement

Intervention Type DEVICE

Measuring blood pressure before and after MRI-scan

Body temperature

Intervention Type DEVICE

Measuring body temperature before and after MRI-scan

Questionnaires

Intervention Type OTHER

Questionnaires at the start of the study on lifestyle. Additionally, a questionnaire before each scan session on the actual state of the volunteer (e.g. mood, caffeine consumption, alcohol, medication, etc.)

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

MRI scan

Several MRI scan modalities: MPRAGE (structural scan), arterial spin labeling (cerebral perfusion), resting state functional-MRI (fMRI, cerebral activity) and diffusion MRI (white matter diffusion and white matter tracts).

Intervention Type DEVICE

Physiological monitoring

During MRI: heart rate, end-tidal carbon dioxide (CO2), respiratory rate and skin conductance

Intervention Type DEVICE

Blood sample

Blood sample after MRI-session: measurement of hematocrit, hemoglobin, estradiol, progesterone, follicle stimulation hormone and luteinizing hormone.

Intervention Type BIOLOGICAL

Blood pressure measurement

Measuring blood pressure before and after MRI-scan

Intervention Type DEVICE

Body temperature

Measuring body temperature before and after MRI-scan

Intervention Type DEVICE

Questionnaires

Questionnaires at the start of the study on lifestyle. Additionally, a questionnaire before each scan session on the actual state of the volunteer (e.g. mood, caffeine consumption, alcohol, medication, etc.)

Intervention Type OTHER

Pregnancy test

Test for pregnancy using a pregnancy dipstick test

Intervention Type DIAGNOSTIC_TEST

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Bachelor or Master student
* Minimum of 3 months not using contraception of using Deso20

Exclusion Criteria

* No informed consent
* MRI-contraindications
* Claustrophobia
* Pregnancy or breastfeeding
* Chronic diseases and chronic medication use
* Smoker
* Drug use
* Abuse of alcohol and caffeine
Minimum Eligible Age

18 Years

Maximum Eligible Age

25 Years

Eligible Sex

FEMALE

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

University Ghent

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Eric Achten, MD, PhD

Role: PRINCIPAL_INVESTIGATOR

University Hospital, Ghent

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Ghent University Hospital

Ghent, , Belgium

Site Status RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

Belgium

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Patricia Clement, Msc

Role: CONTACT

Phone: 9 332 1330

Email: [email protected]

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Patricia Clement, MSc

Role: primary

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

EC/2016/0757

Identifier Type: -

Identifier Source: org_study_id